HOME >> BIOLOGY >> NEWS
Anti-interferon beta antibodies in MS care: A consensus

t for MS," urged Frederick Munschauer, M.D. "As new information becomes available, this should be factored into the patient's care. For now, selection of MS therapy should be based on how effective the treatment is over the long-term in light of the potential impact NAbs can have among these therapies. Currently, if a patient develops NAbs, physicians are forced to consider a more toxic or less effective agent."

What is multiple sclerosis?

Multiple sclerosis (MS) is an autoimmune disease that affects the central nervous system (CNS). The CNS consists of the brain, spinal cord, and the optic nerves. Surrounding and protecting the nerve fibers of the CNS is a fatty tissue called myelin, which helps nerve fibers conduct electrical impulses. Myelin not only protects nerve fibers but also makes their job possible.

In MS, myelin is destroyed in multiple areas, leaving scar tissue. These damaged areas are also known as plaques or lesions, and sometimes the nerve fiber itself is damaged or broken. When myelin or the nerve fiber is destroyed or damaged, the ability of the nerves to conduct electrical impulses to and from the brain is impaired or disrupted, and this produces the various symptoms of MS, such as vision problems, numbness, loss of balance, difficulty walking and paralysis.


'"/>

Contact: Cindy Gessell
cindy.gessell@ketchum.com
201-652-4778
Ketchum
14-Feb-2004


Page: 1 2 3

Related biology news :

1. Researchers find clues about how antibodies specialize
2. Second generation targeted antibodies - Its all in the binding
3. Researchers show autoantibodies occur before lupus in New England Journal of Medicine
4. Programmable antibodies-- hybrid cancer therapy described by scientists at Scripps
5. Bodys own antibodies may drive new strains of HIV
6. Growing human antibodies in algae
7. Blasting antibodies with lasers provides direct way of measuring their flexibilities
8. Ozone produced by antibodies during bacterial killing and in inflammation
9. Artificial antibodies created by new molecular imprinting process
10. Human antibodies against spores found by researchers suggest new tool to detect and treat anthrax
11. Scientists at The Scripps Research Institute discover a previously unknown role for antibodies

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused ... Institute of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine ... and is expected to deliver therapeutic levels of olanzapine for a period of 3 ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... 23, 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ... biopharmaceutical company in China, today announced its financial results for ... Fourth Quarter 2016 Financial Highlights ... 21.7% in RMB terms, or increased by 13.6% in USD ... quarter of 2015. Gross profit increased by ...
(Date:2/23/2017)... 23, 2017 ... per share data, unaudited)Three Months Ended December 31,Twelve Months ... $         ...   89026%Aldurazyme Net Product Revenue ... Net Product Revenue  756025%297303(2)%Vimizim Net ...
Breaking Biology Technology:
Cached News: